| Sargent DJ, Taylor JM
Current issues in oncology drug development, with a focus on Phase II trials. [Journal Article]
J Biopharm Stat 2009; 19(3):556-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Hather GJ, Mackey H
Some notable properties of the standard oncology Phase I design. [Journal Article]
J Biopharm Stat 2009; 19(3):543-55.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Mandrekar SJ, Sargent DJ
Clinical trial designs for predictive biomarker validation: one size does not fit all. [Journal Article, Research Support, N.I.H., Extramural]
J Biopharm Stat 2009; 19(3):530-42.
Abstract | Full Citation | Find Related Articles |
| Kocherginsky M, Cohen EE, Karrison T
Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. [Journal Article]
J Biopharm Stat 2009; 19(3):524-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Fan SK, Venook AP, Lu Y
Design issues in dose-finding Phase I trials for combinations of two agents. [Journal Article]
J Biopharm Stat 2009; 19(3):509-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Cheung YK
Selecting promising treatments in randomized Phase II cancer trials with an active control. [Journal Article, Research Support, N.I.H., Extramural]
J Biopharm Stat 2009; 19(3):494-508.
Abstract | Full Citation | Find Related Articles |
| Sun LZ, Chen C, Patel K
Optimal two-stage randomized multinomial designs for Phase II oncology trials. [Journal Article]
J Biopharm Stat 2009; 19(3):485-93.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Bailey S, Neuenschwander B, Laird G, et al.
A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. [Journal Article]
J Biopharm Stat 2009; 19(3):469-84.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Jung SH, George SL
Between-arm comparisons in randomized Phase II trials. [Journal Article]
J Biopharm Stat 2009; 19(3):456-68.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Onar A, Kocak M, Boyett JM
Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Biopharm Stat 2009; 19(3):437-55.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
  |
